7.55629439322269E-05 -0.00083119238325514 0.000680066495390686 0.00173794771044272 0.00136013299078137 0.00362702130875011 0.00362702130875011 0.00362702130875011
Sign Up Today X
Thanks for submitting the form.
Stockreport

Incyte Announces Promising New Data on Oncology Candidate at ESMO [Yahoo! Finance]

Incyte Corporation (INCY)  More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Shares of Incyte have risen 3.1% year to date compared with the industry's growth of 0.5%. Image Source: Zacks Investment Research Incyte's Promising INCB123667 Data This open-label, dose-escalation and dose-expansion phase I study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of INCB123667 when administered as monotherapy at the recommended dose for expansion (RDE[s]) in participants with selected advanced or metastatic solid tumors. While part 1A (dose escalation) determined the recommended dose of INCB123667 for expansion and the maximum tolerated dose (MTD), part 1B (cohort dose expansion phase) will further explore antitumor activity of INCB123667 as a monotherapy in six tumor-specific cohorts at the RDEs defined in part 1A. The study enrolled patients with advanced or metastatic solid tumors (n=205), including ovarian cancer, endometrial cancer, gastrointestinal cancer, HR+/HER2- breast cancer and triple negative b [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

Incyte Announces Promising New Data on Oncology Candidate at ESMO [Yahoo! Finance]

Incyte Corporation  (INCY) 
More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Shares of Incyte have risen 3.1% year to date compared with the industry's growth of 0.5%. Image Source: Zacks Investment Research Incyte's Promising INCB123667 Data This open-label, dose-escalation and dose-expansion phase I study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of INCB123667 when administered as monotherapy at the recommended dose for expansion (RDE[s]) in participants with selected advanced or metastatic solid tumors. While part 1A (dose escalation) determined the recommended dose of INCB123667 for expansion and the maximum tolerated dose (MTD), part 1B (cohort dose expansion phase) will further explore antitumor activity of INCB123667 as a monotherapy in six tumor-specific cohorts at the RDEs defined in part 1A. The study enrolled patients with advanced or metastatic solid tumors (n=205), including ovarian cancer, endometrial cancer, gastrointestinal cancer, HR+/HER2- breast cancer and triple negative b [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS